EVABAVE Trademark

Trademark Overview


On Monday, May 24, 2021, a trademark application was filed for EVABAVE with the United States Patent and Trademark Office. The USPTO has given the EVABAVE trademark a serial number of 90730812. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Tuesday, October 14, 2025. This trademark is owned by Eli Lilly and Company. The EVABAVE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
evabave

General Information


Serial Number90730812
Word MarkEVABAVE
Filing DateMonday, May 24, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateTuesday, October 14, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 8, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 19, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, May 27, 2021NEW APPLICATION ENTERED
Thursday, January 6, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 19, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 5, 2022ASSIGNED TO EXAMINER
Monday, September 19, 2022SOU TEAS EXTENSION RECEIVED
Friday, September 30, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, October 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 15, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, February 8, 2022PUBLISHED FOR OPPOSITION
Tuesday, February 8, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 5, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, September 19, 2022SOU EXTENSION 1 FILED
Friday, September 30, 2022SOU EXTENSION 1 GRANTED
Wednesday, March 15, 2023SOU EXTENSION 2 FILED
Wednesday, March 15, 2023SOU EXTENSION 2 GRANTED
Friday, March 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 14, 2024SOU EXTENSION 4 FILED
Monday, April 17, 2023SOU TEAS EXTENSION RECEIVED
Monday, April 17, 2023SOU EXTENSION 3 FILED
Monday, April 17, 2023SOU EXTENSION 3 GRANTED
Wednesday, April 19, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 14, 2024SOU EXTENSION 4 GRANTED
Thursday, March 14, 2024SOU TEAS EXTENSION RECEIVED
Friday, March 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 2, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 2, 2024SOU EXTENSION 5 FILED
Wednesday, October 2, 2024SOU EXTENSION 5 GRANTED
Wednesday, October 2, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 14, 2025ABANDONMENT - NO USE STATEMENT FILED
Tuesday, October 14, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED